Corifollitropin alfa versus daily recombinant FSH for ovarian stimulation in women of advanced maternal age: a cost-minimization analysis in an out-of-pocket setting

G. N. Cecchino, B. R. Carvalho, Y. Ramires, R. L. P. Bueno, L. A. Lucio, V. P. Santana · 2026

Read Corifollitropin alfa versus daily recombinant FSH for ovarian stimulation in women of advanced maternal age: a cost-minimization analysis in an out-of-pocket setting by G. N. Cecchino, B. R. Carvalho, Y. Ramires, R. L. P. Bueno, L. A. Lucio, V. P. Santana (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13624120.txt.

Description

Cecchino and five co-authors compared the costs of two fertility drug plans in a 2026 analysis. In Brazil, most fertility care is paid out of pocket, and one cycle can cost more than a month's income. The study focused on women of advanced maternal age, from 35 to 42, who need drugs to stimulate their ovaries.

One plan uses a single long-acting injection, corifollitropin alfa. The other uses daily shots of recombinant FSH. Assuming both work equally well, the authors compared drug prices from the official Brazilian database. The single-injection plan cut costs in every scenario tested. For patients paying themselves, such savings can decide whether treatment starts at all.

Catalog record

CREATORG. N. Cecchino, B. R. Carvalho, Y. Ramires, R. L. P. Bueno, L. A. Lucio, V. P. Santana
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE21 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13624120

Browse the full library · About the Tower of Babel